Matthew Henn
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew Henn
Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Matthew Henn was appointed President, effective March 2, 2026. The proxy statement of Seres Therapeutics, Inc. reports total compensation of $1,014,347 for Matthew Henn in fiscal 2025, including a base salary of $489,300. Disclosed compensation is on record for 4 fiscal years. Matthew Henn has spoken on 2 earnings calls across 1 company, most recently for Seres Therapeutics, Inc. on November 5, 2025.
“On February 27, 2026, the Board of Directors (the "Board") of Seres Therapeutics, Inc. (the "Company") appointed Richard N. Kender, a current member of the Board, to serve as Executive Chair of the Board and as Interim Chief Executive Officer of the Company, Matthew Henn, Ph.D., the Company's Chief Scientific Officer, to the additional role of President, and Kelly Brady, M.S., the Company's Senior Vice President, Clinical Development, to the role of Executive Vice President, Chief Operating Officer, each effective March 2, 2026 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Seres Therapeutics, Inc. (MCRB)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Seres Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Marella Thorell CEO, CFO, Chief Accounting Officer
- Richard N. Kender CEO, Chairman, Board Member
- Roger J. Pomerantz CEO
- Kelly Brady COO
- Kelly Brady, M.S. COO
- David S. Ege CTO
- David Arkowitz Chief Accounting Officer
- Eric Shaff Chief Accounting Officer
- Claire Fraser, Ph.D. Board Member
- Claire M. Fraser, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Seres Therapeutics, Inc. (MCRB) | President and Chief Scientific Officer | $489,300 | $1,014,347 |
| 2022 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Scientific Officer | $450,000 | $1,672,303 |
| 2021 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Scientific Officer | $430,000 | $3,551,792 |
| 2019 | Seres Therapeutics, Inc. (MCRB) | Executive Vice President and Chief Scientific Officer | $385,000 | $859,452 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.